Baker Bros. Advisors LP Nurix Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $9.02 Billion
- Q4 2024
A detailed history of Baker Bros. Advisors LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 3,882,125 shares of NRIX stock, worth $51.8 Million. This represents 0.81% of its overall portfolio holdings.
Number of Shares
3,882,125
Previous 3,882,125
-0.0%
Holding current value
$51.8 Million
Previous $87.2 Million
16.08%
% of portfolio
0.81%
Previous 0.93%
Shares
3 transactions
Others Institutions Holding NRIX
# of Institutions
184Shares Held
67MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$91 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$58 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$55.9 Million6.18% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.01MShares$40.1 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$40 Million2.49% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $629M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...